secwatch.observer — SEC 8-K summary
======================================

Issuer:     Generation Bio Co. (—)
CIK:        0001733294
Form:       8-K
Filed at:   2024-05-13T23:59:59+00:00
Accession:  0001558370-24-007959
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Generation Bio Q1 net loss $74.5M on lease termination; cash runway into 2H 2027
--------------------------------------------------------------------------------

- Q1 net loss $74.5M ($1.12/share) includes $56.9M non-cash lease termination charge; vs $32.1M ($0.53) Q1 2023.
- Cash $233.9M at March 31, 2024; expected to fund operations into 2H 2027.
- Presented in vivo T cell delivery data for ctLNP at ASGCT; advancing HSC-targeted ctLNP for sickle cell/beta-thalassemia.
- R&D expenses $14.3M, down from $22.0M YoY; G&A $10.4M, down from $12.9M.
- Collaboration with Moderna for T cell ctLNP; iqDNA platform using rapid enzymatic synthesis advanced.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1733294/000155837024007959/0001558370-24-007959-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1733294/000155837024007959/gbio-20240513x8k.htm
  HTML page:      https://secwatch.observer/filing/0001558370-24-007959

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer